7 results
Search Results
2. An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.
- Author
-
Pouwels, Xavier G. L. V., Ramaekers, Bram L. T., Geurts, Sandra M. E., Erdkamp, Frans, Vriens, Birgit E. P. J., Aaldering, Kirsten N. A., van de Wouw, Agnes J., Dercksen, M. W., Smilde, Tineke J., Peters, Natascha A. J. B., van Riel, J. M. G. H., Pepels, Manon J., Heijnen-Mommers, Jose, Tjan-Heijnen, Vivianne C. G., de Boer, Maaike, and Joore, Manuela A.
- Subjects
BREAST cancer prognosis ,BREAST tumors ,CANCER chemotherapy ,COST effectiveness ,REPORTING of diseases ,HEALTH insurance reimbursement ,TREATMENT effectiveness ,QUALITY-adjusted life years ,DESCRIPTIVE statistics ,ERIBULIN - Abstract
Background: In 2013, eribulin was reimbursed under a coverage with evidence development (CED) as third or later chemotherapy line for advanced breast cancer (ABC) patients in the Netherlands because of uncertain cost effectiveness. In 2016, the final decision of reimbursing eribulin was taken without considering the evidence collected during CED research. We analysed the cost effectiveness of eribulin versus non-eribulin chemotherapy, using real-world data. Methods: A three health states (progression-free, progressed disease, dead) partitioned survival model was developed. The SOuth East Netherlands Advanced BREast Cancer (SONABRE) registry informed the effectiveness and costs inputs. Health state utility values were obtained from the literature. Incremental cost-effectiveness ratio (ICER) between the eribulin and matched non-eribulin chemotherapy was estimated. Deterministic and probabilistic sensitivity analyses and scenario analyses were performed. The financial risk (i.e., the expected value of perfect information (EVPI) plus the expected monetary loss (eML) associated with reimbursing eribulin) and budget impact associated with reimbursing eribulin were calculated. Results: Eribulin led to higher health benefits (0.07 quality-adjusted life year (QALY)) and costs (€15,321) compared with non-eribulin chemotherapy. This resulted in an ICER of €220,608. At a €80,000 per QALY threshold, the risk of reimbursing eribulin was €9,791 per patient (EVPI €13, eML €9,778). Scaled up to the Dutch population, the estimated annual budget impact was €1.9 million and the annual risk of reimbursing eribulin was €2.7 million. Conclusion: From a Dutch societal perspective, eribulin is not cost effective when considering its list price as third and later chemotherapy line for ABC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Ten weeks to live: A population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands.
- Author
-
Bernards, Nienke, Haj Mohammad, Nadia, Creemers, Geert-Jan, de Hingh, Ignace H. J. T., van Laarhoven, Hanneke W. M., and Lemmens, Valery E. P. P.
- Subjects
PANCREATIC tumors ,AGE distribution ,CANCER chemotherapy ,CHI-squared test ,CONFIDENCE intervals ,METASTASIS ,REGRESSION analysis ,SURVIVAL ,MULTIPLE regression analysis ,DATA analysis software ,DESCRIPTIVE statistics ,ODDS ratio ,TUMOR treatment - Abstract
Background. A large proportion of patients with pancreatic cancer presents with metastatic disease. We conducted a population-based study to evaluate trends in treatment and survival of patients with metastatic pancreatic cancer. Methods. We included all patients diagnosed with pancreatic cancer between 1993 and 2010 in the South of the Netherlands (N = 3099). Multivariable logistic regression analysis was conducted to evaluate trends in treatment with chemotherapy. Crude overall survival according to period of diagnosis was analyzed, and independent risk factors for death were identified. Results. Forty-eight percent of the patients (N = 1494) were diagnosed with metastatic disease. The percentage of patients being diagnosed with metastatic disease increased during the study period from 35% in 1993-1996 to 59% in 2009-2010 (p < 0.0001). Overall, 18% of these patients received chemotherapy. The prescription of palliative chemotherapy almost tripled from 10% to 27% (p < 0.0001). Treatment largely depended on age, ranging from 38% among patients aged < 50 years [compared to 60-69 years: adjusted odds ratio (OR
adj ) 2.5 (95% CI 1.4-4.2)] to 1% among patients aged ≥ 80 years [compared to 60-69 years: ORadj 0.04 (95% CI 0.0-0.2)]. Patients were more likely to receive chemotherapy if they had a high socioeconomic status [ORadj 2.0 (95% CI 1.3-3.1)], and if diagnosis was pathologically verified [no verification vs. verification: ORadj 0.3 (95% CI 0.2-0.5)]. The administration of chemotherapy varied widely between 10 hospitals (5-34%, p < 0.0001). The median overall survival of patients with metastatic pancreatic cancer remained 9-11 weeks. Conclusion. A growing proportion of pancreatic cancer patients presented with metastatic disease. Usage of palliative chemotherapy increased over time, but median survival remained 9-11 weeks. In the near future, it should be evaluated if the recently introduced regimens have an impact on population-based survival. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
4. Chemotherapy as palliative treatment for peritoneal carcinomatosis of gastric origin.
- Author
-
Thomassen, Irene, Bernards, Nienke, van Gestel, Yvette R., Creemers, Geert-Jan, Jacobs, Esther M., Lemmens, Valery E., and de Hingh, Ignace H.
- Subjects
CANCER chemotherapy ,CHI-squared test ,CONFIDENCE intervals ,EPIDEMIOLOGY ,HEALTH outcome assessment ,PALLIATIVE treatment ,PERITONEAL cancer ,STOMACH tumors ,SURVIVAL analysis (Biometry) ,DATA analysis ,TREATMENT effectiveness ,DATA analysis software - Abstract
A letter to the editor is presented related to a population based study conducted to examine trends in systemic treatment and survival of patients with peritoneal carcinomatosis of gastric origin.
- Published
- 2014
- Full Text
- View/download PDF
5. Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia.
- Author
-
van den Hurk, Corina J., van den Akker-van Marle, M. Elske, Breed, Wim P., van de Poll-Franse, Lonneke V., Nortier, Johan W., and Coebergh, Jan W.
- Subjects
BALDNESS ,CANCER chemotherapy ,CHI-squared test ,COLD therapy ,CONFIDENCE intervals ,COST effectiveness ,HEALTH surveys ,LONGITUDINAL method ,QUALITY of life ,QUESTIONNAIRES ,RESEARCH funding ,SCALP ,VISUAL analog scale ,DATA analysis software ,DESCRIPTIVE statistics ,PREVENTION - Abstract
Background. Alopecia is a frequently occurring side effect of chemotherapy that often can be prevented by cooling the scalp during the infusion. This study compared effects and costs of scalp cooling with usual general oncological care, i.e. purchasing a wig or head cover. Material and methods. Scalp-cooled patients (n = 160) were compared with non-scalp-cooled patients (n = 86) at 15 Dutch hospitals. Patients were enrolled prior to anthracycline and/or taxane-based chemotherapy for several types of cancer between 2007 and 2008. Cost-effectiveness of scalp cooling compared with that of usual care was determined by the ratio of costs to quality adjusted life years (QALYs). Costs for scalp cooling (machines and nursing time), hair dressers, wigs and head covers were estimated from a societal perspective. QALYs were measured using the Short Form-36. Results. Scalp cooling reduced the use of a wig or head cover by 40%, but wigs were still purchased unnecessarily by 38% of scalp-cooled patients. Average societal costs decreased therefore only by €269 per patient due to scalp cooling (p = 0.02). Given the eligibility for scalp cooling at the time, the insignificant difference in QALYs resulted from a balance of the benefits for those patients with successful scalp cooling and those without success. For the Dutch, given the generally accepted threshold of willingness to pay for a QALY (between €20 000 and €40 000), scalp cooling was cost-effective, therefore justifying the choice of scalp cooling or purchasing a wig or head cover. Conclusion. Given the right indication, cost-effectiveness might be improved further by postponing wig and head cover purchases, by improving scalp cooling efficacy, as well as using the scalp cooling capacity more intensively. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: A retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
- Author
-
Venderbosch, Sabine, Doornebal, Joan, Teerenstra, Steven, Lemmens, Wim, Punt, Cornelis J. A., and Koopman, Miriam
- Subjects
AGE distribution ,ANTIMETABOLITES ,CANCER chemotherapy ,CHI-squared test ,CLINICAL trials ,COLON tumors ,CONFIDENCE intervals ,DRUG toxicity ,METASTASIS ,MONOCLONAL antibodies ,HEALTH outcome assessment ,QUALITY of life ,QUESTIONNAIRES ,RECTUM tumors ,RESEARCH funding ,STATISTICS ,SURVIVAL ,SECONDARY analysis ,OXALIPLATIN ,TREATMENT effectiveness ,RETROSPECTIVE studies ,DATA analysis software ,DESCRIPTIVE statistics ,IRINOTECAN - Abstract
Background. Metastatic colorectal cancer (CRC) is predominantly a disease of the elderly, therefore the current standards should be evaluated in this population. Material and methods. We evaluated in different age groups the outcome in terms of median overall and progression-free survival, response rate, disease control rate, relative dose intensity (RDI), tolerability, and global quality of life (QoL) of first-line capecitabine monotherapy (CAP) versus capecitabine + irinotecan (CAPIRI) and capecitabine + oxaliplatin + bevacizumab (CAPOX + BEV) in the CAIRO and CAIRO2 study, respectively. Patients were categorized into three age groups: age > 75, 70-75 and < 70 years. Results. Clinical outcomes were not significantly different among age groups, with the exception of a higher response rate from CAP treatment in the elderly. Elderly patients treated with CAPOX + BEV showed a trend towards a worse median overall survival compared to younger patients. Only treatment with CAP resulted in a higher incidence of grade 3-4 toxicity and a lower RDI in elderly versus younger patients. Treatment with CAP and CAPOX + BEV in elderly patients was significantly more often discontinued due to toxicity instead of progression to disease compared to younger patients. The increase in global QoL was comparable for the three age groups for each treatment regimen. Conclusion. We did not observe significant differences in survival outcomes between elderly and younger metastatic CRC patients with three different first-line systemic treatment regimens. Our data suggest that initial dose reduction of CAP monotherapy may be indicated in elderly patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - Results of the Dutch Scalp Cooling Registry.
- Author
-
van den Hurk, Corina J., Peerbooms, Mijke, van de Poll-Franse, Lonneke V., Nortier, Johan W., Coebergh, Jan Willem W., and Breed, Wim P.
- Subjects
BALDNESS ,CANCER chemotherapy ,CHI-squared test ,CONFIDENCE intervals ,EPIDEMIOLOGY ,SCALP ,TEMPERATURE ,U-statistics ,DATA analysis ,MULTIPLE regression analysis ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Background. Chemotherapy-induced alopecia is a frequently occurring side effect of cancer treatment with a high psychological impact which can be prevented by scalp cooling. With this multi-centre patient series we estimated the results of scalp cooling for currently used chemotherapies to provide patient information and we identified characteristics associated with the results. Material and methods. The Dutch Scalp Cooling Registry collected data on scalp-cooled patients in 28 Dutch hospitals. Nurses and patients completed questionnaires on patients, chemotherapy and scalp cooling characteristics. Logistic regression analysis was used to examine associated characteristics of the scalp cooling result. Results. Overall, 50% of the 1411 scalp-cooled patients did not wear a head cover during their last chemotherapy session. Patients were satisfied with the results in 8% of cases after TAC chemotherapy and up to 95% after paclitaxel treatment. Besides type of chemotherapy, higher dose and shorter infusion time, older age, female gender and non-West-European type of hair significantly increased the proportion head cover use. Hair length, quantity, chemical manipulation (dyeing, waving, colouring), wetting hair before scalp cooling, and treatment with chemotherapy ever before did not influence the degree of head covering among patients. Conclusions. Scalp cooling results as recorded in this open patient registry were positive for most regimens, justifying it's use by all eligible patients, except for those needing TAC. Lengthening infusion time may improve the results. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.